Organic Chemistry: Current Research
Open Access
ISSN: 2161-0401
+44 1478 350008
ISSN: 2161-0401
+44 1478 350008
Oncogen Pharma Sdn Bhd, No.3, Jalan Jururancang U1/21, Hicom Glenmarie Industrial Park, 40150 Shah Alam, Selangor, Malaysia
Mini Review
Synthetic Review of Manufacturing Routes to CDK4/6 Inhibitor Drugs: Palbociclib, Ribociclib and Abemaciclib
Author(s): Pawan Kumar*, Suhaila M. Yaman, Muhammad Taufiq F. Mazlee, Premnath Dhande and Sandeep Mhetre
Palbociclib, Ribociclib and Abemaciclib are the drugs categorized as CDK4 and CDK6 cyclin-dependent kinase
inhibitors. The current article reviews the patent and non-patent journals regarding the synthetic routes and final
polymorphic forms of these CDK4/6 inhibitors. Palbociclib (PD0332991, Ibrance®), Ribociclib (LEE011, Kisqali®)
and Abemaciclib (LY2835219, Bemaciclib, Verzenio®) are the drugs approved as cyclin-dependent kinase inhibitors
(CDK4/6) and are used for the treatment of certain kind of breast cancer. Other reported CDK4/6 inhibitor is
Trilaciclib (G1T28) which is still in phase 2 clinical trials. The drug Ribociclib was approved by USFDA on March
13, 2017, Palbociclib was approved by USFDA on March 31, 2017 and Abemaciclib was approved by USFDA on
sept.28, 2017... View More»
DOI:
10.35841/2161-0401.22.11.254